Acne And Related Disorders - Pipeline Review, H2 2012

Global Markets Direct, August 2012, Pages: 178

Acne And Related Disorders – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Acne And Related Disorders - Pipeline Review, H2 2012', provides an overview of the Acne And Related Disorders therapeutic pipeline. This report provides information on the therapeutic development for Acne And Related Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acne And Related Disorders. 'Acne And Related Disorders - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acne And Related Disorders.
- A review of the Acne And Related Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acne And Related Disorders pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acne And Related Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acne And Related Disorders pipeline depth and focus of Acne And Related Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Acne And Related Disorders Therapeutic Products under Development, Key Players in Acne And Related Disorders Therapeutics, Acne And Related Disorders Pipeline Overview, Acne And Related Disorders Pipeline, Acne And Related Disorders Pipeline Assessment

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Acne And Related Disorders Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Acne And Related Disorders 10
Acne And Related Disorders Therapeutics under Development by Companies 12
Acne And Related Disorders Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Acne And Related Disorders Therapeutics – Products under Development by Companies 23
Acne And Related Disorders Therapeutics – Products under Investigation by Universities/Institutes 27
Companies Involved in Acne And Related Disorders Therapeutics Development 28
Photocure ASA 28
QLT Inc. 29
Valeant Pharmaceuticals International 30
GlaxoSmithKline plc 31
Galderma S.A. 32
Meda AB 33
Merz GmbH & Co. KGaA 34
Toyama Chemical Co. Ltd 35
Paratek Pharmaceuticals, Inc. 36
AntiCancer, Inc. 37
Revance Therapeutics, Inc. 38
Helix BioMedix, Inc. 39
Cosmo Pharmaceuticals S.p.A 40
XOMA Ltd. 41
Quest PharmaTech Inc. 42
Summit Corporation plc 43
Phynova Group Ltd 44
Syntopix Group Plc 45
Phosphagenics Limited 46
Foamix Ltd. 47
Novabiotics Ltd 48
Funxional Therapeutics Ltd 49
aRigen Pharmaceuticals, Inc. 50
AndroScience Corporation 51
Hygeia Therapeutics, Inc. 52
NovaLead Pharma Pvt. Ltd. 53
NanoBio Corporation 54
Cutanea Life Sciences 55
Laboratorios SALVAT S.A. 56
Braintree Laboratories, Inc. 57
Maruho Co.,Ltd. 58
Lee's Pharmaceutical Holdings Limited 59
Mimetica Pty Ltd. 60
Fibrocell Sciences, Inc. 61
Ausio Pharmaceuticals, LLC 62
XBiotech USA, Inc. 63
Advancell 64
Acne And Related Disorders – Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Combination Products 66
Assessment by Route of Administration 67
Assessment by Molecule Type 70
Drug Profiles 73
HB1345 - Drug Profile 73
FX125L - Drug Profile 74
Phytobacx - Drug Profile 75
WAP-8294A2 - Drug Profile 77
CLS001 - Drug Profile 79
Tretinoin - Drug Profile 81
IDP-107 - Drug Profile 82
RT001 - Drug Profile 83
HYG-440 - Drug Profile 84
HYG-430 - Drug Profile 86
HYG-420 - Drug Profile 87
HYG-410 - Drug Profile 88
ASC-J9 - Drug Profile 89
Laviv - Drug Profile 90
AUS-131 - Drug Profile 92
SMT D002 - Drug Profile 94
Visonac - Drug Profile 95
Lemuteporfin - Drug Profile 96
Lipo-4MA - Drug Profile 97
XOMA 052 - Drug Profile 98
Drospirenone + Ethinyl Estradiol - Drug Profile 100
Differin + Tetralysal - Drug Profile 102
CB-03-01 - Drug Profile 103
Epiduo + Doxycycline - Drug Profile 105
Autologous Fibroblast Transplantation - Drug Profile 107
NB-003 - Drug Profile 109
FXFM244 - Drug Profile 110
SYN 1163 - Drug Profile 111
Tetracyclines For Acne - Drug Profile 112
Duac Low Dose - Drug Profile 113
DRM-01 - Drug Profile 114
Lappa Arctium - Drug Profile 115
Flutamide - Drug Profile 116
CD07223 - Drug Profile 117
5-Aminolevulinic Acid-Photodynamic Therapy + Adapalene - Drug Profile 118
BLI1100 - Drug Profile 120
ozenoxacin - Drug Profile 121
MTC896 - Drug Profile 123
NLP44 - Drug Profile 125
Skin Infection Project - Drug Profile 126
Acnex - Drug Profile 127
ANT-1207 - Drug Profile 128
CD2475/101 - Drug Profile 129
JNJ 10229570-AAA - Drug Profile 130
M512101 - Drug Profile 131
M108101 - Drug Profile 132
Azithromycin + Levamisole - Drug Profile 133
Doxycycline - Drug Profile 134
SL017 - Drug Profile 136
RA-18C3 - Drug Profile 138
Drug For Acne - Drug Profile 140
Oplon Active Patch - Drug Profile 141
ARK-E021 - Drug Profile 142
HO/04/09 - Drug Profile 143
FibroStem - Drug Profile 144
CD5789 - Drug Profile 145
DS107 (Dignity Sciences) - Drug Profile 146
MUS 92579 - Drug Profile 147
ANs-29 - Drug Profile 148
ZK-008 - Drug Profile 149
Acne And Related Disorders Therapeutics – Drug Profile Updates 150
Acne And Related Disorders Therapeutics – Discontinued Products 160
Acne And Related Disorders Therapeutics - Dormant Products 161
Acne And Related Disorders – Product Development Milestones 166
Featured News & Press Releases 166
Appendix 173
Methodology 173
Coverage 173
Secondary Research 173
Primary Research 173
Expert Panel Validation 173
Contact Us 174
Disclaimer 174

List of Tables
Number of Products Under Development for Acne And Related Disorders, H2 2012 14
Products under Development for Acne And Related Disorders – Comparative Analysis, H2 2012 15
Number of Products under Development by Companies, H2 2012 17
Number of Products under Development by Companies, H2 2012 (Contd..1) 18
Number of Products under Development by Companies, H2 2012 (Contd..2) 19
Number of Products under Development by Companies, H2 2012 (Contd..3) 20
Number of Products under Investigation by Universities/Institutes, H2 2012 22
Comparative Analysis by Late Stage Development, H2 2012 23
Comparative Analysis by Mid Clinical Stage Development, H2 2012 24
Comparative Analysis by Early Clinical Stage Development, H2 2012 25
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 26
Products under Development by Companies, H2 2012 27
Products under Development by Companies, H2 2012 (Contd..1) 28
Products under Development by Companies, H2 2012 (Contd..2) 29
Products under Development by Companies, H2 2012 (Contd..3) 30
Products under Investigation by Universities/Institutes, H2 2012 31
Photocure ASA, H2 2012 32
QLT Inc., H2 2012 33
Valeant Pharmaceuticals International, H2 2012 34
GlaxoSmithKline plc, H2 2012 35
Galderma S.A., H2 2012 36
Meda AB, H2 2012 37
Merz GmbH & Co. KGaA, H2 2012 38
Toyama Chemical Co. Ltd, H2 2012 39
Paratek Pharmaceuticals, Inc., H2 2012 40
AntiCancer, Inc., H2 2012 41
Revance Therapeutics, Inc., H2 2012 42
Helix BioMedix, Inc., H2 2012 43
Cosmo Pharmaceuticals S.p.A, H2 2012 44
XOMA Ltd., H2 2012 45
Quest PharmaTech Inc., H2 2012 46
Summit Corporation plc, H2 2012 47
Phynova Group Ltd, H2 2012 48
Syntopix Group Plc, H2 2012 49
Phosphagenics Limited, H2 2012 50
Foamix Ltd., H2 2012 51
Novabiotics Ltd, H2 2012 52
Funxional Therapeutics Ltd, H2 2012 53
aRigen Pharmaceuticals, Inc., H2 2012 54
AndroScience Corporation, H2 2012 55
Hygeia Therapeutics, Inc., H2 2012 56
NovaLead Pharma Pvt. Ltd., H2 2012 57
NanoBio Corporation, H2 2012 58
Cutanea Life Sciences, H2 2012 59
Laboratorios SALVAT S.A., H2 2012 60
Braintree Laboratories, Inc., H2 2012 61
Maruho Co.,Ltd., H2 2012 62
Lee's Pharmaceutical Holdings Limited, H2 2012 63
Mimetica Pty Ltd., H2 2012 64
Fibrocell Sciences, Inc., H2 2012 65
Ausio Pharmaceuticals, LLC, H2 2012 66
XBiotech USA, Inc., H2 2012 67
Advancell, H2 2012 68
Assessment by Monotherapy Products, H2 2012 69
Assessment by Combination Products, H2 2012 70
Assessment by Stage and Route of Administration, H2 2012 73
Assessment by Stage and Molecule Type, H2 2012 76
Acne And Related Disorders Therapeutics – Drug Profile Updates 154
Acne And Related Disorders Therapeutics – Discontinued Products 164
Acne And Related Disorders Therapeutics – Dormant Products 165
Acne And Related Disorders Therapeutics – Dormant Products (Contd..1) 166
Acne And Related Disorders Therapeutics – Dormant Products (Contd..2) 167
Acne And Related Disorders Therapeutics – Dormant Products (Contd..3) 168
Acne And Related Disorders Therapeutics – Dormant Products (Contd..4) 169

List of Figures
Number of Products under Development for Acne And Related Disorders, H2 2012 14
Products under Development for Acne And Related Disorders – Comparative Analysis, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 21
Late Stage Products, H2 2012 23
Mid Clinical Stage Products, H2 2012 24
Early Clinical Stage Products, H2 2012 25
Discovery and Pre-Clinical Stage Products, H2 2012 26
Assessment by Monotherapy Products, H2 2012 69
Assessment by Combination Products, H2 2012 70
Assessment by Route of Administration, H2 2012 71
Assessment by Stage and Route of Administration, H2 2012 72
Assessment by Molecule Type, H2 2012 74
Assessment by Stage and Molecule Type, H2 2012 75

Customers who bought this item also bought

• Global Acne Drug Pipeline Capsule - 2012
• Bone Disorders – Pipeline Review, H1 2013
• Sleep Disorders – Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Stroke – Pipeline Review, H1 2013
• Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future
• HIV-1 Infection – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Major Depressive Disorder – Pipeline Review, H1 2013